Solubilization of Sirolimus Using SNEDDS Formulations

Rubrik: Originale

(Treffer aus pharmind, Nr. 04, Seite 562 (2015))

Islambulchilar Z | Valizadeh H | Zakeri-Milani P

Solubilization of Sirolimus Using SNEDDS Formulations / Application of Statistical Experimental Design · Islambulchilar Z, Valizadeh H, Zakeri-Milani P · ¹ Student Research Committee and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran und ² School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran und ³ Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran und ⁴ Liver and Gastrointestinal Diseases Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
Dissolution Sirolimus SNEDDS Solubility Solubilization Statistical design Solubility and hence dissolution behavior of drug compounds besides their permeability are critical aspects for their oral bioavailability [ 1 ]. Since a large number of drug candidates are lipophillic in nature and have poor aqueous solubility, solubilization of these poorly soluble drugs presents a major and frequently encountered challenge in the formulation design and development as well as a potential hurdle in their oral delivery [ 2 ]. Numerous formulation approaches have been used to overcome these problems including use of prodrugs, crystal polymorph selection, solid dispersions, inclusion complexes with beta-cyclodextrins, nanoparticles, ...

Sirolimus Nano Liposomes

Rubrik: Originale

(Treffer aus pharmind, Nr. 12, Seite 1924 (2014))

Ghanbarzadeh S | Valizadeh H | Zakeri-Milani P

Sirolimus Nano Liposomes / Optimization of sirolimus nano liposomes prepared by modified ethanol injection method using response surface methodology · Ghanbarzadeh S, Valizadeh H, Zakeri-Milani P · ¹ Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran und ² Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran und ³ Research Center for Pharmaceutical Nanotechnology and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran und ⁴ Liver and Gastrointestinal Diseases Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
Ethanol injection Factorial design Liposome Response surface methodology Sirolimus Sirolimus (Rapamycin, SRL, CAS 53123-88-9) is a macrolide lactone produced by Streptomyces hydroscopicus . It is an immunosuppressive agent used for the prophylaxis of renal allograft rejection. SRL was first isolated from a soil sample from Rapa Nui, an island in the south Pacific. SRL unlike tacrolimus, cyclosporine, mycophenolate and other immunosuppressants has a unique mechanism of action involving the suppression of T-lymphocyte proliferation through inhibition of rapamycin protein kinase complex target. Since 1999 SRL has been approved by the FDA and now it is available as tablet, suspension and stent ...

The Effect of Tween Excipients on Expression and Activity of P-Glycoprotein in Caco-2 Cells

Rubrik: Originale

(Treffer aus pharmind, Nr. 05, Seite 788 (2014))

Hodaei D | Baradaran B | Valizadeh H | Mohammadnezhad L | Zakeri-Milani P

The Effect of Tween Excipients on Expression and Activity of P-Glycoprotein in Caco-2 Cells / Hodaei et al. • Tween Excipients · Hodaei D, Baradaran B, Valizadeh H, Mohammadnezhad L, Zakeri-Milani P · ¹ Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran und ² Drug Applied Research Center and School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran und ³ Research Center for Pharmaceutical Nanotechnology and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran und ⁴ School of medicine, Tabriz University of Medical Sciences, Tabriz, Iran. und ⁵ Liver and Gastrointestinal Diseases Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
Bioavailability Caco-2 Excipient P-Glycoprotein Surfactant Tween Having many advantages, like enhanced patient compliance and easier chronic administration, 85 % of drugs sold around the world are administered orally. Oral delivery is the most preferred route in drug prescription but, unfortunately, nearly 50 % of orally administrated drugs have low bioavailability (BA) due to their poor and inadequate absorption through the intestinal mucosa [ 1 , 2 ]. Active efflux of drugs into the gastrointestinal (GI) lumen is generally recognized as a factor for limiting drug absorption and it is responsible for variability in plasma drug concentrations [ 3 ]. An efflux pump, ...